Alpine Immune Sciences News Releases http://ir.alpineimmunesciences.com/ Alpine Immune Sciences News Releases en Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory Board http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-advances-oncology-programs-new-alpn-202 ALPN-202 Preclinical Data Presented at the Society for Immunotherapy of Cancer’s ( SITC ) 33 rd Annual Meeting Supports First-In-Class Triple Mechanism of Action for the Treatment of Cancer Company Strengthens Scientific Advisory Board with Slate of Oncology Leaders SEATTLE --(BUSINESS WIRE)--Nov. Fri, 09 Nov 2018 08:00:00 -0500 Alpine Immune Sciences News Releases 7751 Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2018 Financial Results http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-provides-corporate-update-and-reports-2 SEATTLE --(BUSINESS WIRE)--Nov. 8, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for autoimmune/inflammatory diseases and cancer, today provided a corporate update and reported financial results for the third quarter Thu, 08 Nov 2018 16:35:00 -0500 Alpine Immune Sciences News Releases 7736 Alpine Immune Sciences to Present at Two Upcoming Investor Conferences http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-present-two-upcoming-investor-0 SEATTLE --(BUSINESS WIRE)--Nov. 5, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming investor Mon, 05 Nov 2018 07:00:00 -0500 Alpine Immune Sciences News Releases 7721 Alpine Immune Sciences Announces Scientific Presentations at 60th American Society of Hematology Annual Meeting and Exposition http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-announces-scientific-presentations-60th SEATTLE --(BUSINESS WIRE)--Nov. 1, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the 60 th American Society Thu, 01 Nov 2018 11:14:00 -0400 Alpine Immune Sciences News Releases 7716 Alpine Immune Sciences’ Lead Program ALPN-101 Demonstrates Preclinical Activity in Inflammatory Arthritis and Neurological Inflammation http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-lead-program-alpn-101-demonstrates Data from experimental models of inflammatory arthritis and multiple sclerosis presented at 2018 ACR/ARHP Annual Meeting and 143 rd Annual Meeting of the American Neurological Association ALPN-101 has completed CMC scale up and is poised to be the first dual ICOS /CD28 antagonist in clinic in Q1 Mon, 22 Oct 2018 07:00:00 -0400 Alpine Immune Sciences News Releases 7711 Alpine Immune Sciences to Present at Society for Immunotherapy of Cancer 33rd Annual Meeting http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-present-society-immunotherapy-cancer-33rd SEATTLE --(BUSINESS WIRE)--Oct. 4, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the Society for Thu, 04 Oct 2018 16:05:00 -0400 Alpine Immune Sciences News Releases 7706 Alpine Immune Sciences to Present at Ladenburg Thalmann 2018 Healthcare Conference http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-present-ladenburg-thalmann-2018 SEATTLE --(BUSINESS WIRE)--Sep. 25, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the Ladenburg Thalmann 2018 Tue, 25 Sep 2018 07:00:00 -0400 Alpine Immune Sciences News Releases 7681 Alpine Immune Sciences Announces Upcoming Scientific Presentations http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-announces-upcoming-scientific-0 ALPN-101 preclinical data to be presented at the 2018 ACR/ARHP Annual Meeting and the 143 rd Annual Meeting of the American Neurological Association SEATTLE --(BUSINESS WIRE)--Sep. 24, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing Mon, 24 Sep 2018 07:00:00 -0400 Alpine Immune Sciences News Releases 7671 Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2018 Financial Results http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-provides-corporate-update-and-reports-1 SEATTLE --(BUSINESS WIRE)--Aug. 9, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and Thu, 09 Aug 2018 16:05:00 -0400 Alpine Immune Sciences News Releases 7646 Alpine Immune Sciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-reports-inducement-grant-under-nasdaq SEATTLE --(BUSINESS WIRE)--Aug. 8, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases, today reported the grant of an equity inducement award to Mark Litton , Wed, 08 Aug 2018 18:00:00 -0400 Alpine Immune Sciences News Releases 7631